Isoniazid/rifampicinAlternative Names: Rifampicin/isoniazid
Latest Information Update: 03 Nov 2015
At a glance
- Originator Pfizer
- Class Antibacterials; Hydrazines
- Mechanism of Action Cell wall inhibitors; DNA-directed RNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis